HC Wainwright Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $87.00

Denali Therapeutics (NASDAQ:DNLI) had its price target cut by HC Wainwright from $90.00 to $87.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ FY2026 earnings at ($0.58) EPS, FY2027 earnings at $1.82 EPS, FY2028 earnings at $4.16 EPS and FY2029 earnings at $6.29 EPS.

Other equities research analysts have also issued research reports about the stock. William Blair initiated coverage on shares of Denali Therapeutics in a report on Friday, January 3rd. They issued an “outperform” rating for the company. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research report on Monday, December 16th. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. cut their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $38.91.

Denali Therapeutics Stock Up 0.3 %

Shares of NASDAQ:DNLI opened at $21.25 on Tuesday. The firm has a fifty day simple moving average of $24.23 and a two-hundred day simple moving average of $24.86. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $33.33. The stock has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the firm posted ($0.72) earnings per share. On average, analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insiders Place Their Bets

In other Denali Therapeutics news, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the transaction, the director now directly owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander O. Schuth sold 15,558 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the sale, the insider now owns 178,066 shares of the company’s stock, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,518 shares of company stock worth $2,576,982 over the last 90 days. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently modified their holdings of the business. Victory Capital Management Inc. grew its stake in Denali Therapeutics by 163.7% during the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after purchasing an additional 24,767 shares during the last quarter. FMR LLC boosted its position in Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after buying an additional 7,596,508 shares during the last quarter. Algert Global LLC increased its holdings in Denali Therapeutics by 82.4% in the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company’s stock worth $1,417,000 after buying an additional 21,975 shares during the period. Integral Health Asset Management LLC purchased a new position in Denali Therapeutics during the 2nd quarter worth approximately $7,546,000. Finally, Principal Financial Group Inc. lifted its stake in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after acquiring an additional 149,939 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.